Advertisement
BMY vs MRK
Which Stock Would AI Choose? Bristol-Myers Squibb (BMY) vs. Merck & Co. (MRK) Stock Comparison
Key Takeaways
- Bristol-Myers Squibb (BMY) and Merck & Co. (MRK) are two pharmaceutical titans competing in oncology, immunology, and cardiometabolic markets, each with distinct pipeline strategies.
- Merck's dominant oncology franchise, led by Keytruda, continues to drive robust revenue growth, while Bristol-Myers faces patent cliffs on key legacy drugs including Eliquis and Opdivo in the coming years.
- Both stocks have experienced divergent price trajectories in recent months, influenced by clinical trial results, regulatory news, and shifting investor sentiment around their respective pipelines.
- Bristol-Myers has been actively pursuing an acquisition-driven growth strategy, notably with its recent M&A (Mergers and Acquisitions) activity in neuroscience and targeted oncology, as it works to offset looming revenue losses.
- Merck offers a comparatively more predictable earnings profile supported by Keytruda's durability, while BMY's current valuation may present a different risk-reward profile for value-oriented investors.
- Tickeron's AI-driven analysis evaluates both stocks through trend strength, volatility patterns, and momentum indicators to objectively assess which ticker currently holds a relative edge.
Introduction
When evaluating major pharmaceutical stocks, BMY and MRK consistently emerge as two of the most closely watched names in the healthcare sector. Bristol-Myers Squibb and Merck & Co. each command market capitalizations exceeding $100 billion, maintain deep oncology portfolios, and generate tens of billions in annual revenue. Yet their recent stock performance, growth trajectories, and strategic priorities diverge in meaningful ways. This comparison is particularly relevant for healthcare-focused investors, dividend seekers evaluating yield and capital appreciation potential, and traders monitoring relative strength within the pharmaceutical industry. Understanding how these two industry leaders stack up against one another can help contextualize broader sector trends and inform portfolio positioning decisions.
BMY Overview and Recent Performance
Bristol-Myers Squibb is a global biopharmaceutical company with leading franchises in oncology, immunology, cardiovascular disease, and neuroscience. The company's portfolio includes blockbuster drugs such as Eliquis (a blood thinner co-marketed with Pfizer), Opdivo (an immunotherapy treatment), and Revlimid (a multiple myeloma therapy acquired through the Celgene purchase). In recent weeks, BMY has navigated mixed market conditions, with its stock experiencing periods of pressure tied to ongoing investor concerns about the patent cliff facing several key products. Revlimid has already begun facing generic competition, and Eliquis is expected to see Medicare price negotiation impacts under the Inflation Reduction Act in the years ahead. To counter these headwinds, Bristol-Myers has pursued an aggressive M&A strategy, completing notable acquisitions in the neuroscience and oncology spaces. Recent clinical trial data releases and regulatory updates across its pipeline—including developments in its next-generation immunology and cell therapy programs—have drawn significant analyst attention. The company's cost-savings initiatives and restructuring efforts have also shaped sentiment, with the market closely monitoring how effectively management navigates the transition toward newer growth assets.
MRK Overview and Recent Performance
Merck & Co. stands as one of the world's largest pharmaceutical companies, anchored by Keytruda, the top-selling cancer immunotherapy globally with annual revenues exceeding $25 billion. Beyond oncology, Merck's portfolio spans vaccines (including Gardasil, the HPV vaccine), animal health, and a growing cardiovascular presence. In recent market activity, MRK has demonstrated relatively resilient performance, bolstered by Keytruda's continued expansion into new indications and treatment settings. The drug's subcutaneous formulation advances and ongoing clinical successes in earlier-stage cancers have reinforced confidence in its long-duration revenue stream. However, Merck has not been without challenges. Gardasil sales have faced headwinds in certain international markets, particularly China, where shipment timing and macroeconomic factors have introduced volatility. The company's pipeline investments in cardiometabolic disease, including sotatercept for pulmonary arterial hypertension, represent significant potential growth catalysts that the market has been monitoring closely. Additionally, Merck's disciplined approach to business development—including targeted bolt-on acquisitions—has been viewed favorably as management balances growth investment with shareholder returns. The stock's relative stability compared to certain pharmaceutical peers has attracted investors seeking defensive healthcare exposure with meaningful innovation upside.
Trending AI Robots
Tickeron's Trending AI Robots page offers traders and investors access to a curated selection of AI-powered trading bots from a broader universe of hundreds available on the platform. These bots collectively trade thousands of different tickers, but only those demonstrating the strongest alignment with current market conditions earn a place in the Trending section. The featured bots employ varied trading styles—from short-term momentum strategies to longer-duration swing and trend-following approaches—with some generating annualized returns that have drawn considerable interest from the trading community. Each bot comes with detailed transparency into its historical performance, win/loss ratios, maximum drawdown statistics, and the specific tickers it trades, allowing users to evaluate suitability before committing. The curated nature of this section means readers can quickly identify which automated strategies are presently optimized for prevailing market dynamics. To explore the top-performing AI trading bots available now, visit the Trending AI Robots page and review the current lineup.
Head-to-Head Comparison
When comparing BMY and MRK directly, several contrasting dynamics emerge. On the revenue durability front, Merck holds a clearer advantage: Keytruda's patent protection extends well into the late 2020s, and its expanding indication list provides multi-year growth visibility. Bristol-Myers, by contrast, faces nearer-term patent expirations on Eliquis and continued erosion from Revlimid generics, forcing more urgent pipeline execution. In terms of valuation, BMY trades at a notably lower forward price-to-earnings (P/E) multiple than MRK, reflecting the market's discounting of its patent cliff risk—this creates a potential value opportunity but also underscores genuine uncertainty. Growth drivers differ as well: Merck leans on organic pipeline advancement and Keytruda combination strategies, while Bristol-Myers has relied more heavily on M&A to reshape its portfolio, a higher-risk but potentially transformative approach. From a dividend perspective, both offer attractive yields relative to the broader market, though BMY's higher yield has come under scrutiny given earnings transition risk. On recent momentum, MRK has generally displayed steadier price action, while BMY has experienced sharper sentiment swings around clinical and regulatory developments. Sector exposure is broadly similar given their pharmaceutical concentration, but Merck's animal health division and vaccine breadth provide modest diversification that Bristol-Myers lacks.
Tickeron AI Verdict
Based on observable factors including trend consistency, earnings visibility, and relative price stability, Tickeron's AI-driven analysis would likely favor MRK in the current market environment. Merck's more durable revenue base—anchored by Keytruda's extended growth runway—combined with steadier technical patterns and fewer near-term patent cliff uncertainties, provides a foundation for more consistent trend-following signals. The stock's relative resilience during periods of sector weakness further supports a probabilistic tilt in its favor. That said, BMY is not without merit: its compressed valuation and aggressive pipeline strategy could generate stronger upside catalysts if key clinical programs deliver positive results or strategic acquisitions begin contributing meaningfully to revenue. The AI's preference for MRK reflects a relative assessment of stability and trend reliability rather than an absolute judgment, and the balance could shift depending on how each company's upcoming catalysts materialize in the months ahead.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a StrongBuy and MRK is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 3 FA rating(s) are green whileMRK’s FA Score has 2 green FA rating(s).
- BMY’s FA Score: 3 green, 2 red.
- MRK’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 6 TA indicator(s) are bullish while MRK’s TA Score has 5 bullish TA indicator(s).
- BMY’s TA Score: 6 bullish, 3 bearish.
- MRK’s TA Score: 5 bullish, 4 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а +2.22% price change this week, while MRK (@Pharmaceuticals: Major) price change was +2.80% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.95%. For the same industry, the average monthly price growth was +1.76%, and the average quarterly price growth was +4.67%.
Reported Earning Dates
BMY is expected to report earnings on Jul 30, 2026.
MRK is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.95% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| BMY | MRK | BMY / MRK | |
| Capitalization | 127B | 324B | 39% |
| EBITDA | 15B | 19.4B | 77% |
| Gain YTD | 18.999 | 26.345 | 72% |
| P/E Ratio | 17.39 | 36.92 | 47% |
| Revenue | 48.5B | 65.8B | 74% |
| Total Cash | N/A | N/A | - |
| Total Debt | 46.4B | 49.1B | 95% |
BMY | MRK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 33 | 32 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 4 Undervalued | 87 Overvalued | |
PROFIT vs RISK RATING 1..100 | 83 | 42 | |
SMR RATING 1..100 | 25 | 47 | |
PRICE GROWTH RATING 1..100 | 14 | 8 | |
P/E GROWTH RATING 1..100 | 54 | 7 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BMY's Valuation (4) in the Pharmaceuticals Major industry is significantly better than the same rating for MRK (87). This means that BMY’s stock grew significantly faster than MRK’s over the last 12 months.
MRK's Profit vs Risk Rating (42) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (83). This means that MRK’s stock grew somewhat faster than BMY’s over the last 12 months.
BMY's SMR Rating (25) in the Pharmaceuticals Major industry is in the same range as MRK (47). This means that BMY’s stock grew similarly to MRK’s over the last 12 months.
MRK's Price Growth Rating (8) in the Pharmaceuticals Major industry is in the same range as BMY (14). This means that MRK’s stock grew similarly to BMY’s over the last 12 months.
MRK's P/E Growth Rating (7) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (54). This means that MRK’s stock grew somewhat faster than BMY’s over the last 12 months.
| BMY | MRK | |
|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 50% |
| Stochastic ODDS (%) | 3 days ago 56% | 3 days ago 52% |
| Momentum ODDS (%) | 3 days ago 54% | 3 days ago 59% |
| MACD ODDS (%) | 3 days ago 59% | 3 days ago 54% |
| TrendWeek ODDS (%) | 3 days ago 53% | 3 days ago 56% |
| TrendMonth ODDS (%) | 3 days ago 57% | 3 days ago 55% |
| Advances ODDS (%) | 3 days ago 54% | 3 days ago 55% |
| Declines ODDS (%) | 26 days ago 55% | 7 days ago 51% |
| BollingerBands ODDS (%) | 3 days ago 56% | 3 days ago 52% |
| Aroon ODDS (%) | 3 days ago 67% | 3 days ago 65% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| MXSFX | 10.24 | 0.23 | +2.30% |
| Empower Real Estate Index Instl | |||
| SCAVX | 17.72 | 0.05 | +0.28% |
| AB Small Cap Value A | |||
| BGATX | 13.79 | N/A | N/A |
| Baillie Gifford Global Alpha Equities 2 | |||
| RPGIX | 25.56 | -0.07 | -0.27% |
| T. Rowe Price Global Industrials | |||
| BDSAX | 22.86 | -0.08 | -0.35% |
| BlackRock Advantage Small Cap Core Inv A | |||
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with NVS. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then NVS could also see price increases.